**All Interactions with Abacavir (Ziagen)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Abacavir** | **Effect on Drug Levels** | **Effect on Abacavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#60)  (APV)(Agenerase) | 900 mg BID x 3 weeks | 300 mg BID x 3 weeks | Amprenavir Cmax: increased 47%; AUC: increased 29%; Cmin: increased 27% | Not studied | - | - | Dose adjustment not established |
| Ethanol[212](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#212),[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#66)  (Alcohol, Ethanol, Wine, Liquor, Beer, Spirits) | 0.7 g/kg body weight | 600 mg QD | No significant change | Abacavir AUC: increased 41%; half-life: increased 26% | - | Decreased abacavir metabolism by alcohol dehydrogenase | No dose adjustment necessary |
| Lamivudine[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#66),[67](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#67)  (3TC)(Epivir) | 150 mg x 1 dose | 600 mg x 1 dose | Lamivudine Cmax: decreased 35%; AUC: decreased 15% | No significant change | - | Delayed lamivudine absorption | No dose adjustment necessary |
| Methadone[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#66)  (Dolophine)(Dolophine) | 40 mg QD; 90 mg QD | 600 mg BID | Methadone clearance: increased 22% | No significant change | Decreased methadone effects (eg, withdrawal) | - | Monitor for signs and symptoms of methadone withdrawal; some patients may need an increase in the methadone dose |
| Mycophenolate[312](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#312)  (CellCept)(CellCept) | 500 mg BID x 8 weeks | 300 mg BID | Not studied | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Abacavir** | **Effect on Drug Levels** | **Effect on Abacavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Tenofovir disoproxil fumarate[135](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#135)  (TDF)(Viread) | 300 mg QD x 13 days | 300 mg BID | No significant change | No significant change | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#154)  (TPV)(Aptivus) | 1250 mg BID with 100 mg ritonavir BID x 42 doses | 300 mg BID x 43 doses | - | Abacavir AUC: decreased 35%; Cmax: decreased 52% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#154)  (TPV)(Aptivus) | 250 mg BID with 200 mg ritonavir BID | 300 mg BID x 43 doses | - | Abacavir AUC: decreased 44%; Cmax: decreased 44% | - | - | No dose adjustment necessary |
| Tipranavir[154](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#154)  (TPV)(Aptivus) | 750 mg BID with 100 mg ritonavir BID | 300 mg BID x 43 doses | - | Abacavir AUC: decreased 36%; Cmax: decreased 46% | - | - | No dose adjustment necessary |
| Zidovudine[68](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#68)  (AZT, ZDV)(Retrovir) | 200 mg TID, 300 mg BID | 200 mg TID, 400 mg TID, 600 mg TID, 300 mg BID | Not studied | Inconsistent effect across all dosing regimens | - | - | No dose adjustment necessary |
| Zidovudine[66](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#66),[67](http://arv.ucsf.edu/insite?page=ar-00-02&param=21&post=4#67)  (AZT, ZDV)(Retrovir) | 300 mg x 1 dose | 600 mg x 1 dose | Zidovudine Cmax: decreased 20%; AUC: no significant change | No significant change | - | Delayed zidovudine absorption | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 66: | Ziagen [package insert]. Research Triangle Park, NC: GlaxoWellcome Inc.; Sept 2005. |
| 67: | Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 1999;43:1708-15. |
| 68: | McDowell JA, Lou Y, Symonds WS, et al. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000;44:2061-67. |
| 135: | Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [abstract #A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois. |
| 154: | Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005. |
| 212: | McDowell JA, Chittick GE, Stevens CP, et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000;44:1686-90. |
| 312: | Sankatsing S, Hoggard P, Back D, et al. Mycophenolate mofetil lowers plasma nevirapine concentrations but has no effect on intracellular triphospate concentrations [abstract #539]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |